Welcome to our dedicated page for RAMM PHARMA news (Ticker: RAMMF), a resource for investors and traders seeking the latest updates and insights on RAMM PHARMA stock.
RAMM PHARMA CORP (RAMMF) delivers pharmaceutical innovations through rigorously validated research and strategic academic partnerships. This news hub provides investors and healthcare professionals with essential updates on the company's scientific advancements and regulatory progress.
Access timely updates on clinical trial developments, regulatory submissions, and research collaborations. Our curated news collection ensures stakeholders stay informed about RAMMF's evidence-based approach to drug development and quality-controlled manufacturing processes.
Key updates include progress reports on therapeutic formulations, partnership announcements with research institutions, and compliance milestones in global pharmaceutical markets. All content reflects the company's commitment to transparency and scientific validation through peer-reviewed methodologies.
Bookmark this page for direct access to official RAMMF communications, including analysis of research outcomes and strategic initiatives. Regularly updated to serve as your primary resource for understanding the company's position in pharmaceutical innovation.
RAMM Pharma Corp. has updated its shareholders on ongoing litigation involving Sergio Martines and Naturale Science Inc. The trial occurred between April 29, 2024, and May 16, 2024, with the judge reserving the decision. Martines and Naturale Science Inc. are demanding approximately C$3 million from RAMM for breach of contract, specific performance, and out-of-pocket expenses. In response, RAMM has filed a counterclaim seeking C$14 million in damages for alleged fraudulent misrepresentation related to its acquisition of Canapar in June 2021. RAMM has accrued C$300,000 in its financial statements for possible liabilities, which may be adjusted in future reports.
FAQ
What is the market cap of RAMM PHARMA (RAMMF)?
